Clinical Trial Update: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating doravirine/islatravir combination in treatment-naïve HIV-1 patients; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) (doravirine/islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2023-11-21